Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma ...Middle East

PR Newswire - News
Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma
DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted...

Hence then, the article about lantern pharma announces launch of antibody drug conjugate adc program to target solid tumors blood cancers through agreement with califia pharma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma )

Apple Storegoogle play

Last updated :

Also on site :



Latest News